ReviewPituitary2015
Surgical management of Cushing's disease.
Review in Pituitary, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 43 citations in OpenAlex.
- Phosphoproteomic dysregulation promotes tumor proliferation in Cushing's disease.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Specific focus on the basal dura for improving Cushing's disease surgery: a cohort study.Neurosurgical review · 2025Article
- Cost outcomes of pituitary adenoma resection: The use of a hybrid microscopic/endoscopic surgery.Surgical neurology international · 2025Article
- No requirement of perioperative glucocorticoid replacement in patients with endogenous Cushing's syndrome - a pilot study.Endocrine · 2024Article
- Review
- Surgical outcome of transsphenoidal surgery in Cushing's disease: a case series of 1106 patients from a single center over 30 years.Endocrine · 2022Article
- Diagnostic Pitfalls in Cushing Disease: Surgical Remission Rates, Test Thresholds, and Lessons Learned in 105 Patients.The Journal of clinical endocrinology and metabolism · 2022Article
- Prediction of recurrence and remission within 3 years in patients with Cushing disease after successful transnasal adenomectomy.Pituitary · 2019Article
- Cushing's Disease.Journal of clinical medicine · 2019Review
- Review
- Functioning Pituitary Adenomas - Current Treatment Options and Emerging Medical Therapies.European endocrinology · 2019Review
- Review
- Earlier post-operative hypocortisolemia may predict durable remission from Cushing's disease.European journal of endocrinology · 2018Article
- Consensus-driven in-hospital cortisol assessment after ACTH-secreting pituitary adenoma resection.Pituitary · 2018Article
- Outcome of endoscopic vs microsurgical transsphenoidal resection for Cushing's disease.Endocrine connections · 2018Review
- Clinicopathological predictive factors in the early remission of corticotroph pituitary macroadenomas in a tertiary referral centre.European journal of endocrinology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranssphenoidal selective adenomectomy is the first-line treatment for Cushing's disease. At experienced centers, early remission rates after transsphenoidal surgery range from 65 to 98%, however disease relapse frequently occurs with rates ranging from 2 to 35% at long-term follow up.
methodsThis article discusses recently reported studies on the surgical outcomes from transsphenoidal surgery for Cushing's disease.
conclusionsOne of the keys to a successful long-term surgical outcome is meticulous dissection using the adenoma's pseudocapsule as a surgical plane for complete resection. MRI-negative and invasive ACTH-secreting adenomas pose particular challenges for pituitary surgeons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.